A Phase II Trial of Continuous 5-Fluorouracil in Recurrent or Metastatic Transitional Cell Carcinoma of the Urinary Tract

Clinical Oncology

Volumn 21, Issue 5, 2009, Pages 394-400

  Highley, M S ^a   Griffiths, G O ^b   Uscinska, B M ^b   Huddart, R A ^c   Barber, J B P ^d   Parmar, M K B ^b   Harper, P G ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Fluorouracil; transitional cell carcinoma; urological neoplasms

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; ATAXIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; INTESTINE OBSTRUCTION; KIDNEY DISEASE; LACRIMATION; LETHARGY; LEUKOPENIA; LUNG EMBOLISM; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENT CANCER; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT CARCINOMA; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; VEIN THROMBOSIS;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; FEMALE; FLUOROURACIL; HUMANS; INFUSION PUMPS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; UROLOGIC NEOPLASMS;

EID: 67349228039     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.01.011     Document Type: Article

References (26)

1. Cancer Research UK. CancerStats, 2005.
2. Loehrer P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066-1073
3. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (1997) 2564-2569
4. Mead G.M., Russell M., Clark P., et al. A randomised trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. Br J Cancer 78 (1998) 1067-1075
5. Von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
6. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 60 (1987) 574-585
7. Logothetis C.J., Hossan E., Sella A., Dexeus F.H., and Amato R.J. Fluorouracil and recombinant human interferon alpha-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst 83 (1991) 285-288
8. Huan S.D., Aitken S.E., and Stewart D.J. A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer. Ann Oncol 6 (1995) 836-837
9. Meta-analysis Group in Cancer. Efficacy of continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16 (1998) 301-308
10. Findlay M., Cunningham D., Norman A., et al. A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5 (1994) 609-616
11. Jones A.L., Smith I.E., O'Brien M.E., et al. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol 12 (1994) 1259-1265
12. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephrology 16 (1976) 31-41
13. Bern M.M., Lokich J.J., Wallach S.R., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112 (1990) 423-428
14. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
15. Lin C.-C., Hsu C.-H., Huang C.-Y., et al. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma. Cancer 106 (2006) 1269-1275
16. Siefker-Radtke A.O., Millikan R.E., Tu S.-M., et al. Phase III trial of fluorouracil, interferon alfa-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20 (2002) 1361-1367
17. Di Lorenzo G., Autorino R., Giordano A., et al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J Clin Oncol 34 (2004) 747-750
18. Sternberg C.N., de Mulder P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42 (2006) 50-54
19. Moore M.J., Tannock I.F., Ernst D.S., Huan S., and Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15 (1997) 3441-3445
20. Stadler W.M., Kuzel T., Roth B., Raghavan D., and Dorr F.A. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15 (1997) 3394-3398
21. Roth B.J., Dreicer R., Einhorn L.H., et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12 (1994) 2264-2270
22. Heinemann V. Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol 29 Suppl 3 (2002) 25-35
23. Smorenburg C.H., Sparreboom A., Bontenbal M., and Verweij J. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer 37 (2001) 2310-2323
24. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19 (2001) 4097-4106
25. Arima J., Imazono Y., Takebayashi Y., et al. Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 88 (2000) 1131-1138
26. Patel B., Forman J., Fontana J., Frazier A., Pontes E., and Vaishampayan U. A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. Int J Radiat Oncol Biol Phys 62 (2005) 1332-1338